

**Commission on Narcotic Drugs****Sixty-eighth session**

Vienna, 10–14 March 2025

Item 5 (a) of the provisional agenda*

Implementation of the international drug control treaties: changes in the scope of control of substances**Control of substances under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988: notification from the President of the International Narcotics Control Board****Note by the Secretariat***Summary*

The present document contains information and a proposal for consideration by the Commission on Narcotic Drugs pursuant to the international drug control treaties.

Pursuant to article 12, paragraph 13, of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988, the Commission is to review periodically the adequacy and propriety of Tables I and II of the Convention. Accordingly, the Commission will have before it, for review, a notification from the President of the International Narcotics Control Board concerning a proposal to move the methyl ester of 3,4-MDP-2-P methyl glycidic acid from the body of Table I of the Convention to footnote 1 to that Table as introduced in accordance with Commission decision 67/25.

* [E/CN.7/2025/1](#).



I. Background

1. At its sixty-seventh session, held in March 2024, the Commission on Narcotic Drugs decided to include the ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl esters of 3,4-MDP-2-P methyl glycidic acid in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (Commission decisions 67/18 to 67/24).
2. Furthermore, through its decision 67/25, the Commission decided to include the ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl esters of 3,4-MDP-2-P methyl glycidic acid in Table I of the 1988 Convention in the form of a footnote to 3,4-MDP-2-P methyl glycidic acid.

II. Notification from the International Narcotics Control Board concerning scheduling under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988

3. On 4 September 2024, in accordance with article 12, paragraph 4, of the 1988 Convention, the President of the International Narcotics Control Board notified the Chair of the Commission on Narcotic Drugs that the Board had identified an inconsistency in the manner in which the esters of 3,4-MDP-2-P methyl glycidic acid were presented in Table I of the 1988 Convention.
4. The Board had found that while seven esters of 3,4-MDP-2-P methyl glycidic acid were included in a footnote pursuant to Commission decision 67/25 of March 2024, the methyl ester, which had been added to Table I in November 2019, was still included in the body of that table (as 3,4-MDP-2-P methyl glycidate (“PMK glycidate”). As communicated by the President, the Board therefore proposed that the methyl ester be removed from the body of Table I of the 1988 Convention and included in the same footnote so that it appeared together with the other seven esters (as the “methyl ester”).
5. The notification from the President of the Board and a schematic presentation of the Board’s proposal are contained in the annex to the present document, for consideration by the Commission at its sixty-eighth session.

III. Action to be taken by the Commission on Narcotic Drugs

6. The Commission, at its sixty-eighth session, will be asked to take action on the Board’s proposal to move 3,4-MDP-2-P methyl glycidate (“PMK glycidate”) from the body of Table I of the 1988 Convention to footnote 1 to that table, as “methyl ester”, so that it appears together with the other seven esters of 3,4-MDP-2-P methyl glycidic acid.

Annex

Notification from the President of the International Narcotics Control Board to the Chair of the Commission on Narcotic Drugs at its sixty-eighth session concerning a proposal to move the methyl ester of 3,4-MDP-2-P methyl glycidic acid from the body of Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 to the footnote introduced in accordance with Commission decision 67/25

1. The President of the International Narcotics Control Board presents his compliments to the Chair of the Commission on Narcotic Drugs and has the honour to inform him that the Board, in conformity with its role under article 12, paragraphs 2 and 4, of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (hereafter referred to as “the 1988 Convention”), has identified an inconsistency in the manner in which the esters of 3,4-MDP-2-P methyl glycidic acid are currently presented in Table I of the 1988 Convention.
2. The Board has found that while seven esters of 3,4-MDP-2-P methyl glycidic acid are included in a footnote pursuant to Commission decision 67/25 of March 2024, the methyl ester, which was added to Table I in November 2019, is still included in the body of that table (as 3,4-MDP-2-P methyl glycidate (“PMK glycidate”). The Board is therefore proposing that the methyl ester be removed from the body of Table I of the 1988 Convention and included in the same footnote together with the other seven esters (as “methyl ester”). This would also be consistent with the presentation of P-2-P methyl glycidic acid and its esters in the same table (Commission decision 67/17).
3. A schematic presentation of the Board’s proposal is set out in the appendix to the present notification and has been prepared for submission to the Commission at its sixty-eighth session.

Appendix

Proposed amendments to Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988

Tables of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988, as at 3 December 2024

<i>Table I</i>	<i>Table II</i>
Acetic anhydride	Acetone
<i>N</i> -Acetylanthranilic acid	Anthranilic acid
4-Anilino- <i>N</i> -phenethylpiperidine (ANPP)	Ethyl ether
<i>tert</i> -Butyl 4-oxopiperidine-1-carboxylate (1-boc-4-piperidone)	Hydrochloric acid ^a
<i>tert</i> -Butyl 4-(phenylamino)piperidine-1-carboxylate (1-boc-4-AP)	Methyl ethyl ketone
Ephedrine	Piperidine
Ergometrine	Sulphuric acid ^a
Ergotamine	Toluene
Isosafrole	
Lysergic acid	
3,4-MDP-2-P methyl glycidate ("PMK glycidate")	
3,4-MDP-2-P methyl glycidic acid ("PMK glycidic acid") and selected esters ¹	
3,4-Methylenedioxyphenyl-2-propanone (3,4-MDP-2-P)	
Methyl <i>alpha</i> -phenylacetoacetate (MAPA)	
Norephedrine	
Norfentanyl	
<i>N</i> -Phenethyl-4-piperidone (NPP)	
Phenylacetic acid	
<i>alpha</i> -Phenylacetoacetamide (APAA)	
<i>alpha</i> -Phenylacetoacetonitrile (APAAN)	
<i>N</i> -Phenyl-4-piperidinamine (4-AP)	
1-Phenyl-2-propanone (P-2-P)	
P-2-P methyl glycidic acid ("BMK glycidic acid") and selected esters ²	
4-Piperidone	
Piperonal	
Potassium permanganate	
Pseudoephedrine	
Safrole	

Proposal:

Delete "3,4-MDP-2-P methyl glycidate ("PMK glycidate")" from the body of Table I and add "Methyl" at the beginning of footnote 1.

¹ **Methyl**, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, and *tert*-butyl esters of 3,4-MDP-2-P methyl glycidic acid.

² Methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, and *tert*-butyl esters of P-2-P methyl glycidic acid.